🇺🇸 FDA
Patent

US 11331333

Treatment of aberrant fibroblast proliferation

granted A61KA61K31/343A61K31/713

Quick answer

US patent 11331333 (Treatment of aberrant fibroblast proliferation) held by The Board of Regents of the University of Texas System expires Mon May 12 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue May 17 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 12 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K31/343, A61K31/713